About: Rapid Establishment of a COVID‐19 Convalescent Plasma Program in a Regional Healthcare Delivery Network

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Rapid Establishment of a COVID‐19 Convalescent Plasma Program in a Regional Healthcare Delivery Network Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Rapid Establishment of a COVID‐19 Convalescent Plasma Program in a Regional Healthcare Delivery Network
Creator	Katz, Louis Pherez, Francisco Frey, Sharon Blackall, Douglas Goel, Ruchika Jacobs, Lauren Jamkhana, Zafar Lacasse, Alexandre Patri, Manokiran Roettger, Timothy Smith, Linda Wulff, Shephali Zinser, Phillip
Source	Medline; PMC
abstract	BACKGROUND: COVID‐19 convalescent plasma (CCP) represents an appealing approach to the treatment of patients with infections due to SARS‐CoV‐2. We endeavored to quickly establish a sustainable CCP transfusion program for a regional network of healthcare facilities. STUDY DESIGN AND METHODS: A regional collaborative group was activated to address the issues necessary to implementing a CCP transfusion program and making the program sustainable. A wide range of healthcare providers including physicians (critical care, infectious disease, transfusion medicine), nurses, pharmacists, laboratorians, and information technology specialists were required to make the program a success. RESULTS: The CCP implementation team initially consisted of 4 members but quickly grew to a group of nearly 20 participants based on different issues related to program implementation. Overall, 6 major implementation “themes” were addressed: (1) registration of individual hospitals and principle investigators with a national investigational new drug research protocol, (2) collaboration with a regional blood donor center, (3) targeted recruitment of convalesced donors, (4) information technology issues related to all aspects of CCP ordering, distribution, and transfusion, (5) prioritization of patients to receive CCP, and (6) evaluation of CCP products including antibody characteristics and patient response to therapy. CONCLUSION: Within 4 weeks of initiation, CCP was successfully transfused at multiple hospitals in our regional healthcare delivery system. A program infrastructure was established that will make this program sustainable into the future. This approach has broader implications for the success of multi‐institutional programs requiring rapid implementation.
has issue date	2020-08-04(xsd:dateTime)
bibo:doi	10.1111/trf.16026
bibo:pmid	32748963
has license	no-cc
sha1sum (hex)	b14d6eaefe91dedc3300defba37d38cbc6777515
schema:url	https://doi.org/10.1111/trf.16026
resource representing a document's title	Rapid Establishment of a COVID‐19 Convalescent Plasma Program in a Regional Healthcare Delivery Network
has PubMed Central identifier	PMC7436587
has PubMed identifier	32748963
schema:publication	Transfusion
resource representing a document's body	covid:b14d6eaefe91dedc3300defba37d38cbc6777515#body_text
is schema:about of	named entity 'Mississippi' named entity 'Establishment' named entity 'COVID-19' covid:arg/b14d6eaefe91dedc3300defba37d38cbc6777515 named entity 'infectious disease' named entity 'critical care' named entity 'activated' named entity 'pharmacists' named entity 'Healthcare' named entity 'Regional' named entity 'pharmacists' named entity 'infectious disease' named entity 'transfusion medicine' named entity 'COVID-19' named entity 'Healthcare Delivery' named entity 'COVID' named entity 'COVID' named entity 'FDA' named entity 'spike proteins' named entity 'IgM' named entity 'clinical microbiology' named entity 'infectious disease' named entity 'COVID-19 pandemic' named entity 'transfusion' named entity 'Ebola virus epidemic in West Africa' named entity 'asymptomatic' named entity 'laboratory services' named entity 'vaccine' named entity 'antibody' named entity 'Mississippi Valley' named entity 'SARS-CoV-2' named entity 'Convalescent plasma' named entity 'virus' named entity 'critically ill' named entity 'anti-viral' named entity 'plasma' named entity 'therapeutic interventions' named entity 'IgG' named entity 'Oklahoma' named entity 'spike protein' named entity 'IND' named entity 'H1N1' named entity 'transfusion' named entity 'antigen' named entity 'severe or life-threatening' named entity 'SARS-CoV-2' named entity 'convalescent plasma' named entity 'infectious diseases' named entity 'SARS-CoV-2' named entity 'not-for-profit' named entity 'Mayo Clinic' named entity 'Wuhan' named entity 'standard operating procedure' named entity 'convalescent plasma transfusion' named entity 'COVID' named entity 'apheresis' named entity 'Missouri' named entity 'COVID' named entity 'Clinical Trial' named entity 'IND' named entity 'SARS' named entity 'transfusion' named entity 'immune response' named entity 'SSM Health' named entity 'IND' named entity 'nucleic acid test' named entity 'COVID' named entity 'convalescent plasma' named entity 'coronavirus infections'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software